{"doi":"10.1016/j.jaad.2021.09.016","title":"Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry","abstract":"To the Editor: Hidradenitis suppurativa (HS) patients may be at increased risk of severe COVID-19 and poor outcomes due to comorbidities and biologic treatment.1Naik H.B. Alhusayen R. Frew J. et al.Global Hidradenitis Suppurativa COVID-19 Registry: a registry to inform data-driven management practices.Br J Dermatol. 2020; 183: 780-781Crossref PubMed Scopus (14) Google Scholar COVID-19 cases in HS patients were reported in the Global Hidradenitis Suppurativa COVID-19 Registry (https://hscovid.ucsf.edu/) from April 5, 2020, to February 2, 2021.1Naik H.B. Alhusayen R. Frew J. et al.Global Hidradenitis Suppurativa COVID-19 Registry: a registry to inform data-driven management practices.Br J Dermatol. 2020; 183: 780-781Crossref PubMed Scopus (14) Google Scholar Eligible cases had confirmed diagnosis of HS by a health care provider (HCP) or screening questions and COVID-19 diagnosis by an HCP. Comparisons were performed using the Fisher's exact or Pearson χ2 test. Multivariable logistic regression was used to predict outcomes based on biologic use, adjusting for demographic features and comorbidities. One hundred ninety-two and 44 cases were entered in the patient and HCP registries, respectively. Forty self-reported cases were incomplete. The descriptive characteristics of 135 eligible self-reported and 44 eligible HCP-reported cases are presented in Table I. Tumor necrosis factor inhibitors were the most commonly used biologic (self-reported: 22/25, 88.0%; and HCP: 19/22, 86.3%). No myocardial infarctions, strokes, or deaths were reported.Table IPatient characteristicsCharacteristicsPatient/Caregiver-reported casesHealth care provider-reported casesBiologicNo biologicAllBiologicNo biologicAllNumber25110135222244Age, y (median, IQR)34 (32-46)31 (26-39)33 (26-41)34 (27-42)33 (28-39)33.5 (27.5-41)Female sex22 (88.0%)100 (90.9%)122 (90.4%)13 (59.1%)15 (71.4%)28 (65.1%)Race/ethnicity White16 (64.0%)79 (71.8%)95 (70.4%)11 (50.0%)7 (31.8%)18 (40.9%) Black African2 (8.0%)2 (1.8%)4 (3.0%)0 (0%)4 (18.2%)4 (9.1%) Black African American2 (8.0%)3 (2.8%)5 (3.7%)4 (18.2%)1 (4.6%)5 (11.4%) Asian0 (0%)1 (0.9%)1 (0.7%)1 (4.6%)1 (4.6%)2 (4.5%) Hispanic3 (12.0%)13 (11.8%)16 (11.8%)3 (13.6%)1 (4.6%)4 (9.1%) Mixed race2 (8.0%)8 (7.3%)10 (7.4%)0 (0%)2 (9.1%)2 (4.6%) Other0 (0%)4 (3.7%)4 (3.0%)2 (9.1%)3 (13.6%)5 (11.4%)Country United States22 (88.0%)56 (50.9%)78 (57.8%)8 (36.4%)5 (22.7%)13 (29.6%) United Kingdom1 (4.0%)14 (12.7%)15 (11.1%)5 (22.7%)3 (13.6%)8 (18.2%) Brazil0 (0%)15 (13.6%)15 (11.1%)1 (4.6%)0 (0%)1 (2.3%) Sweden0 (0%)13 (11.8%)13 (9.6%)−−− France−−−1 (4.6%)10 (45.5%)11 (25.0%) Italy−−−4 (18.2%)1 (4.6%)5 (11.4%) Other11 (10.1%)2 (8.0%)13 (9.7%)∗Other category includes 1-3 cases each from Argentina, Austria, Canada, Denmark, Ireland, Peru, Saudi Arabia, and Spain.3 (13.7%)3 (13.7%)6 (13.7%)†Other category includes 1-2 cases each from Argentina, Canada, Czech Republic, Israel, and Saudi Arabia.Comorbidities Obesity17 (68.0%)72 (65.5%)89 (65.9%)7 (31.8%)6 (27.3%)13 (29.6%) Diabetes1 (4.0%)4 (3.6%)5 (3.7%)4 (18.2%)2 (9.1%)6 (13.7%) Pulmonary disease10 (40.0%)22 (20.0%)32 (23.7%)2 (9.1%)2 (9.1%)4 (9.1%) Tobacco smoking4 (16.0%)19 (17.3%)23 (17.0%)−−− CV disease1 (4.0%)3 (2.7%)4 (3.0%)2 (9.1%)0 (0%)2 (4.6%)Hurley stage Hurley 13 (12.0%)26 (23.6%)29 (21.5%)2 (9.1%)5 (22.7%)7 (15.9%) Hurley 211 (44.0%)49 (45.5%)60 (45.2%)7 (31.8%)10 (45.6%)17 (38.6%) Hurley 39 (36.0%)21 (19.1%)30 (22.2%)13 (59.1%)7 (31.8%)20 (45.5%) Unknown2 (8.0%)13 (11.8%)15 (11.1%)−−−CV, Cardiovascular; IQR, interquartile range.∗ Other category includes 1-3 cases each from Argentina, Austria, Canada, Denmark, Ireland, Peru, Saudi Arabia, and Spain.† Other category includes 1-2 cases each from Argentina, Canada, Czech Republic, Israel, and Saudi Arabia. Open table in a new tab CV, Cardiovascular; IQR, interquartile range. Among the self-reported cases, the odds of hospitalization (biologic: 3/25 [12%]; nonbiologic: 19/110 [17.4%], odds ratio 0.34, P = .16) or oxygen requirement (","journal":"Journal of the American Academy of Dermatology","year":2021,"id":191299,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":13,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9432,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":406407,"name":"Raed Alhusayen","orcid":"0000-0001-6506-9568","position":1,"is_corresponding":false},{"id":273426,"name":"John W. Frew","orcid":"0000-0001-5042-3632","position":2,"is_corresponding":false},{"id":406408,"name":"Sandra Guilbault","orcid":"0000-0002-7732-6215","position":3,"is_corresponding":false},{"id":250061,"name":"Nancy K. Hills","orcid":"0000-0002-1041-8182","position":4,"is_corresponding":false},{"id":395445,"name":"John R Ingram","orcid":"0000-0002-5257-1142","position":5,"is_corresponding":false},{"id":756407,"name":"Margaret V. Kudlinski","orcid":"0000-0001-7196-733X","position":6,"is_corresponding":false},{"id":18935,"name":"Michelle A. Lowes","orcid":"0000-0003-4256-478X","position":7,"is_corresponding":false},{"id":303654,"name":"Angelo Valerio Marzano","orcid":"0000-0002-8160-4169","position":8,"is_corresponding":false},{"id":258597,"name":"Maia Paul","orcid":"0000-0002-6018-1558","position":9,"is_corresponding":false},{"id":395444,"name":"Bente Villumsen","orcid":"0000-0002-5176-2166","position":10,"is_corresponding":false},{"id":407937,"name":"Christine A. Yannuzzi","orcid":null,"position":11,"is_corresponding":false},{"id":258593,"name":"Haley B. Naik","orcid":"0000-0003-2760-3904","position":0,"is_corresponding":true}],"reference_count":5,"raw_metadata":null,"created_at":"2026-07-18T23:49:31.121780Z","pmid":"34537252","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}